23andMe
ME

$0.44

1.76%

Market Cap: 223M

About: 23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.

Employees: 582

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

0

News positive %

of 5 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

11% more call options, than puts

Call options by funds: $105K | Put options by funds: $95K

0% more funds holding in top 10

Funds holding in top 10: 6 [Q4 2023] → 6 (+0) [Q1 2024]

2% less repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 42

4.3% less ownership

Funds ownership: 43.19% [Q4 2023] → 38.89% (-4.3%) [Q1 2024]

13% less funds holding

Funds holding: 167 [Q4 2023] → 145 (-22) [Q1 2024]

47% less capital invested

Capital invested by funds: $123M [Q4 2023] → $65.2M (-$57.6M) [Q1 2024]

58% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 38

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target

$0.47

7%

upside

Avg. target

$0.47

7%

upside

High target

$0.47

7%

upside

1 analyst rating

0 positive

0%

1 neutral

100%

0 negative

0%

Citigroup

Daniel Grosslight

7%upside

$0.47

Neutral

Maintained

16 Apr 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about ME published over the past 30 days

23andMe to Report Q1 FY2025 Financial Results

SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the first quarter of fiscal year 2025 (FY2025) after the market closes on Thursday, August 8, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's results and report on business progress.

23andMe to Report Q1 FY2025 Financial Results

Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research

Study aims to build a comprehensive, open-source database of heritable genetics and patient-reported data in lung cancer Study aims to build a comprehensive, open-source database of heritable genetics and patient-reported data in lung cancer

Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research

The 3 Best Personalized Nutrition Stocks to Buy Now

It could be quite beneficial to invest in personalized nutrition stocks for this month in July. Some applications in the personalized nutrition market are now using artificial intelligence and machine learning, or ML, to provide consumers with more targeted and therefore better advice on their diet.

The 3 Best Personalized Nutrition Stocks to Buy Now

23ANDME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates 23andMe Holding Co. - ME

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the potential take-private transaction of 23andMe Holding Co. (NasdaqCM: ME) (the “Company”). If you would like to discuss your legal rights regarding the potential transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768.

23ANDME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates 23andMe Holding Co. - ME

23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel

SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in biomarker testing and risk prediction, today announced a strategic collaboration to pilot Nightingale Health's clinically-validated and cost-effective blood metabolomics panel with a cohort of 23andMe members.

23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel

23andMe Data Breach - Hackers Targeted Jewish and Chinese Users Data

NEW YORK, NY / ACCESSWIRE / June 14, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.

23andMe Data Breach - Hackers Targeted Jewish and Chinese Users Data

23andMe Holding Co (NASDAQ:ME) Jewish and Chinese Users

NEW YORK, NY / ACCESSWIRE / June 11, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.

23andMe Holding Co (NASDAQ:ME) Jewish and Chinese Users

3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition

Penny stocks are some of the most affordable investments on the market, valued at less than $5. They can hold a unique and intriguing position that can be highly profitable.

3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition

Genetic testing firm investigated over hack

A joint investigation into a data breach at DNA testing company has been launched by UK and Canadian watchdogs.

Genetic testing firm investigated over hack

UK and Canada privacy watchdogs investigating 23andMe data breach

Privacy watchdogs in the U.K. and Canada have launched a joint investigation into the data breach at 23andMe last year.

UK and Canada privacy watchdogs investigating 23andMe data breach

See News Rankings